← All trials
NCT04528641
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 10, 2020
- Primary completion
- Jul 31, 2021
- Completion date
- Jul 31, 2021
- First posted
- Aug 27, 2020
- Last posted
- Aug 31, 2020
- Enrollment
- 90
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- ReiThera SrlLead sponsor
- Istituto Nazionale Malattie Infettive Lazaro SpallanzaniCollaborator
- Istituto Nazionale Malattie Infettive Lazaro SpallanzaniOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.